TECH OUTLOOK 6DECEMBER - 2022EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comDrug discovery and development technologies play a crucial role in shrinking the massive process and reducing the timeline with minimal errors. Pharma companies are increasingly leveraging artificial intelligence, supply chain automation, and data integration technologies to optimize the process, and this is expected to grow the drug discovery and development market size to $161.76 billion by 2027, at a CAGR of 8.9 percent.Like every other industry, artificial intelligence is largely influencing the pharmaceutical industry, especially drug development. Artificial intelligence in drug discovery and development aims to simplify the review of literature and identify potential participants from patients for clinical trials, which, according to Insider Intelligence, can reduce the time and cost of pharmaceutical companies by up to 70 percent.To put the spotlight on similar developments in the industry, Pharma Tech Outlook illustrates how the pharmaceutical industry is leveraging the latest developments in drug discovery and development. The edition also features a thought leadership article from Nick Thomson, Senior Director, Chemical Research & Development, Pfizer [NYSE:PFE]. They shed light on various technological developments that benefit drug discovery and development.In this edition of Pharma Tech Outlook, we also bring to you the story of some of the top drug discovery solution providers in APAC that deliver the best outcomes for their clients. In the list, MediRama particularly stands out for their unique approach, based on their understanding of the clinical development of drugs and expertise that aligns with patient benefits. The list also comprises Metabolon for assisting clients on metabolomics and helping them achieve research and development goals.Through the following pages, we aim to shine a light on the innovative trends and latest developments in the drug discovery and development industry. We would like to know your thoughts.Optimizing Drug Development with Artificial IntelligenceTECH OUTLOOKCopyright © 2022 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.TECH OUTLOOKDECEMBER - 19 - 2022, Vol 08 - Issue 15 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: * Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:VisualizerRonald DonovanParley Meadow
< Page 5 | Page 7 >